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abstract: Several studies have demonstrated an association between polycystic ovary syndrome (PCOS) and the dinucleotide repeat
microsatellite marker D19S884, which is located in intron 55 of the ﬁbrillin-3 (FBN3) gene. Fibrillins, including FBN1 and 2, interact with latent
transforming growth factor (TGF)-b-binding proteins (LTBP) and thereby control the bioactivity of TGFbs. TGFbs stimulate ﬁbroblast repli-
cation and collagen production. The PCOS ovarian phenotype includes increased stromal collagen and expansion of the ovarian cortex, fea-
tures feasibly inﬂuenced by abnormal ﬁbrillin expression. To examine a possible role of ﬁbrillins in PCOS, particularly FBN3, we undertook
tagging and functional single nucleotide polymorphism (SNP) analysis (32 SNPs including 10 that generate non-synonymous amino acid
changes) using DNA from 173 PCOS patients and 194 controls. No SNP showed a signiﬁcant association with PCOS and alleles of most
SNPs showed almost identical population frequencies between PCOS and control subjects. No signiﬁcant differences were observed for
microsatellite D19S884. In human PCO stroma/cortex (n ¼ 4) and non-PCO ovarian stroma (n ¼ 9), follicles (n ¼ 3) and corpora lutea
(n ¼ 3) and in human ovarian cancer cell lines (KGN, SKOV-3, OVCAR-3, OVCAR-5), FBN1 mRNA levels were approximately 100
times greater than FBN2 and 200–1000-fold greater than FBN3. Expression of LTBP-1 mRNA was 3-fold greater than LTBP-2. We conclude
that FBN3 appears to have little involvement in PCOS but cannot rule out that other markers in the region of chromosome 19p13.2 are
associated with PCOS or that FBN3 expression occurs in other organs and that this may be inﬂuencing the PCOS phenotype.
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder
that affects an estimated 5–7% of women of reproductive age in
western societies and is characterized by hyperandrogenemia,
chronic anovulation and polycystic ovaries (Knochenhauer et al.,
1998; Diamanti-Kandarakis et al., 1999). Hirsuitism is common
among women who suffer from the disorder, and they are at increased
risk of anovulatory infertility, obesity (Conway et al., 1989; Balen et al.,
1995), hyperlipidaemia and predisposing factors for heart disease (Wild
et al., 1985; Wild and Bartholomew, 1988; Slowinska-Srzednicka et al.,
1991; Wild et al., 1992; Talbott et al., 1995) and type II diabetes
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the aetiology of PCOS is unknown, familial studies have demonstrated
heritability of the disorder, suggesting that there is a genetic com-
ponent (reviewed in Amato and Simpson, 2004). Female ﬁrst-degree
relatives display strong association between the metabolic abnormal-
ities of PCOS and hyperandrogenemia (Legro et al., 2002; Yildiz
et al., 2003), and a recent study demonstrated that the brothers of
women with PCOS also have a strong association with metabolic
abnormalities (Urbanek et al., 2007). This suggests a common
genetic association between the metabolic features of PCOS and
hyperandrogenemia, whether that be a defect in the same gene or
multiple genes in the same pathway.
The mode of inheritance of PCOS has proven difﬁcult to determine
suggesting that the disorder is a complex trait possibly involving mul-
tiple genes and/or environmental inﬂuences. Many genes in the
steroid synthesis pathways (Carey et al., 1994; Gharani et al., 1997),
the regulatory pathways of gonadotrophin action (Franks, 1995) and
the insulin-signalling pathway have been investigated for association
with the disorder. Many of these studies, however, have proven incon-
clusive or are not reproducible. In contrast, several studies using inde-
pendent patient cohorts have demonstrated a signiﬁcant association
between PCOS and the dinucleotide repeat microsatellite marker
D19S884, which is located 1cM upstream of the insulin receptor
(INSR) gene in chromosome region19p13.2 (Tucci et al., 2001; Villuen-
das et al., 2003; Urbanek et al., 2005; Urbanek et al., 2007). The dis-
tance of this marker from INSR casts doubt upon the likelihood of
there being a causal genetic variant within INSR and it is more probable
that variant(s) in a distal enhancer of INSR or an unrelated gene are the
reason for the association between D19S884 and PCOS. D19S884 is
located within intron 55 of the ﬁbrillin-3 gene (FBN3).
Fibrillins and latent TGF-b-binding proteins (LTBPs) form a family of
proteins that are characterized by a modular domain structure com-
prising epidermal growth factor-like (EGF) domains, calcium-binding
EGF domains and unique cysteine-rich TB domains. Three ﬁbrillin
genes, FBN1, 2 and 3 (Sakai et al., 1986; Lee et al., 1991; Corson
et al., 2004), and four LTBP genes, LTBP 1, 2, 3 and 4 (Kanzaki
et al., 1990; Moren et al., 1994; Yin et al., 1995; Giltay et al., 1997),
have been identiﬁed in mammals, although in rodents FBN3 has
been disrupted due to chromosomal rearrangements (Corson et al.,
2004). FBN3 is most highly expressed in human fetal tissues and the
human adult brain, eye, lung, adrenal glands, stomach and ovaries
(Wheeler et al., 2003; Corson et al., 2004). Studies of FBN1 and 2
have shown that they function as structural components of elastin
ﬁbres or mircroﬁbrils and as regulators of TGF-b family members.
Regulation of TGF-b activity by the ﬁbrillins is a result of their ability
to bind to LTBPs causing sequestration of latent TGF-bs into the
extracellular matrix where they are stored and/or activated
(Ramirez and Pereira, 1999; Kielty et al., 2002; Neptune et al.,
2003). However, there are subtle differences between them. For
instance, LTBP-2 itself does not bind latent TGF-bs (Gibson et al.,
1995), but can competitively replace LTBP-1 bound to FBN1 (Hirani
et al., 2007). LTBPs are also required for the correct secretion and
folding of TGF-bs (Miyazono et al., 1991). To date, interactions
between FBN3 and LTBPs have not been investigated. Clinical conse-
quences of the disruption of the interaction between the ﬁbrillins and
TGF-bs have been reported previously in the pathogenesis of Marfan’s
syndrome, a connective tissue disorder affecting the limbs, the heart,
the lungs and the eyes. Mutations in FBN1 or the TGF-b type 2 recep-
tor cause Marfan’s syndrome (Boileau et al., 2005). The ability of
mutations in FBN1 to phenocopy those in TGF-bR type 2 suggests
that the structural role of FBN1 in the formation of elastic ﬁbres
and microﬁbrils is less critical to the pathology of the disease than
its role in regulating the bioavailability of TGF-b family members.
The involvement of the TGF-b superfamily in the development of
PCOS has been implied from functional data (Glister et al., 2005,
2006) and the association of several members, including anti-Mullerian
hormone (AMH), activin, inhibin and their associated receptors, as
well as follistatin, and the SMADS, has been examined (Urbanek
et al., 1999; Urbanek et al., 2000; Kevenaar et al., 2008). Strong associ-
ation of these genes with PCOS has not been demonstrated, however,
it has been suggested that both follistatin, which like ﬁbrillins and
LTBPs, contain a TB domain (Thompson et al., 2005), and AMH
may contribute to the severity of the PCOS phenotype by inﬂuencing
androgen levels and/or follicle development (Urbanek et al., 2000;
Jones et al., 2007; Kevenaar et al., 2008). Women with PCOS not
only display aberrant follicle maturation, but also develop a thickening
of the tunica albuginea and stromal tissues of their ovaries that is
associated with an increase of collagen deposition in these regions
(Hughesdon, 1982). TGF-b superfamily members have been impli-
cated in the regulation of collagen synthesis by ﬁbroblasts in ﬁbroses;
TGF-b promotes collagen expression and ﬁbrosis while bone mor-
phogenic protein (BMP)7 suppresses these effects (Govinden and
Bhoola, 2003; Wang et al., 2003; Zeisberg et al., 2003; Verrecchia
and Mauviel, 2004; Christner and Ayitey, 2006). Hence we have con-
sidered the possibility that the ﬁbrillin/LTBP protein family members
may be involved in both the gross ovarian morphological and follicular
developmental defects associated with PCOS through a disruption in
ﬁbrillin-LTBP interactions resulting in perturbations in TGF-b signalling
pathways. For these reasons, we chose to undertake a case–control
PCOS association test of 32 single nucleotide polymorphisms
(SNPs) within FBN3. We included non-synonymous SNPs located in
the coding region of the gene with the aim of identifying
PCOS-associated FBN3 variants that may lead to disrupted protein
function. We also examined the RNA expression proﬁles of ﬁbrillin/
LTBP family members in human ovarian tissues and cell lines.
Materials and Methods
Subjects for DNA genotyping
Ethics approval for this study was obtained from the University of Adelaide
Human Research Ethics Committee. Case subjects were recruited from
infertility and antenatal clinics at The Queen Elizabeth Hospital in Adelaide,
South Australia, after approval by the ethics committee of North Western
Adelaide Health Services. Details of a number of these subjects have been
reported previously (Milner et al. 1999). The study group represented
women of various European cultural backgrounds who generally can be
classiﬁed as Caucasian. Case subjects consisted of women with PCOS
deﬁned as hyperandrogenism and chronic anovulation as per the 1990
NIH consensus criteria (Zawadski and Dunaif, 1992). Polycystic ovaries
were identiﬁed on ultrasound and deﬁned as the presence of at least
eight peripheral cysts less than 10 mm in diameter, with increased
ovarian stroma occurring bilaterally (Adams et al., 1986). A total of 367
women between the ages of 18 and 42 were recruited and of these,
173 (47%) women fulﬁlled the criteria for PCOS. A further 86 patients
830 Prodoehl et al.from the same clinics but who had none of the characteristics of PCOS,
and largely male-factor related reasons for infertility, served as controls.
An additional 108 patients whose PCO status was unknown were
recruited from the female blood donor population (Milner et al., 1999).
All samples were de-identiﬁed for further analysis.
DNA extraction
Peripheral blood lymphocytes were puriﬁed from whole blood using Lym-
phoprep (Nycomed Pharma, Oslo, Norway) and kept frozen in saline at
2208C until DNA extraction. DNA was extracted from this tissue using
a DNeasy Kit (QIAGEN, Chatsworth, CA) as per the manufacturer’s pro-
tocol, quantiﬁed by spectrophotometry and stored at 2208C.
Analyses of SNPs
We typed a single multiplex of 32 tagging and functional SNPs spanning an
82 kb region of FBN3. Tagging SNPs (a set of SNPs that through high
linkage disequilibrium (LD) capture the variation in other common SNPs
in the region) were chosen using genotyping data from the International
HapMap Project (http://www.hapmap.org/) from a population of Cauca-
sian and European background (CEU), having minor allelic frequencies of
.0.05 and r
2 values of .0.8. Additional functional SNPs that produce a
change in protein sequence were chosen to complete the multiplex
using genotyping data from the SNP database at the National Library of
Medicine (http://www.ncbi.nlm.nih.gov/snp), such that they would not
interfere with the multiplexing of the tagging SNPs. All SNP sequences
were downloaded from the Chip Bioinformatics database (http://snpper.
chip.org/) and the sequences were cross checked with the National
Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.
gov/) and Sequenom RealSNP databases (https://www.realsnp.com/)
before assay design. Assays were designed for the 32 SNPs using the
Sequenom MassARRAY Assay Design software (version 3.1). SNPs
were typed using iPLEX TM Gold chemistry and analysed using a Sequenom
MassARRAY Compact Mass Spectrometer (Sequenom Inc, San Diego, CA
, USA). The 2.5 mL PCR reactions were performed in standard 384-well
plates using 12.5 ng genomic DNA, 0.8 unit of Taq polymerase (HotStar-
Taq, Qiagen, Valencia, CA), 500 mmol of each dNTP, 1.625 mM of MgCl2
and 100 nmol of each PCR primer (Bioneer, Daejeon, Korea). PCR
thermal cycling in an ABI-9700 instrument was 15 min at 948C, followed
by 45 cycles of 20 s at 948C, 30 s at 568C and 60 s at 728C. To the com-
pleted PCR reaction, 0.15 U shrimp alkaline phosphatase was added and
incubated for 40 min at 378C followed by inactivation for 5 min at 858C.
A mixture of extension primers was tested to adjust the concentrations
of extension primers to equilibrate signal-to-noise ratios in the matrix-
assisted laser desorption/ionization 2 time of ﬂight (MALDI-TOF) mass
spectrometry prior to use for extension reactions. The post-PCR
reactions were performed in a ﬁnal 5 ml of extension reaction containing
1  termination mix, 1 U DNA polymerase and 570– 1240 nM extension
primers. A two-step 200 short cycle programme was used for the iPLEX
Gold reaction as described in a previously study (Zhao et al., 2006). The
iPLEX reaction products were desalted by diluting samples with 15 mlo f
water and adding 5 ml of resin (Sequenom Inc, San Diego, CA, USA).
The products were spotted on a SpectroChip (Sequenom Inc), and data
were processed and analysed by MassARRAY TYPER 3.4 software
(Sequenom Inc).
Microsatellite genotyping
To detect microsatellite D19S884 alleles we designed our own primers
(Table I) rather than using those suggested for amplimer AFMa299zc5
listed in Genbank as we found these to be unreliable. Primers were
designed using Primer Express software (Applied Biosystems, Foster
City, CA, USA), from the published genomic sequence of human FBN3
(Table I). The ampliﬁcation reactions were performed using 50 ng
genomic DNA, 1 U of Taq polymerase (AmpliTaq Gold, PE Applied Bio-
systems) in 1.56 mM MgCl2, 0.1 mM of each dNTP and 10 nmol of each
primer. The cycling conditions were 958C initially for 7 min followed by
40 cycles of 958C, 558C and 728C of 30 s each, then a ﬁnal extension
of 30 min at 728C. The ﬂuorescent PCR products were assayed by
capillary electrophoresis and visually analysed using the ABI 3730 DNA
Analyser (Applied Biosystems) with GeneScan Analysis software. Allele
lengths were conﬁrmed by DNA sequencing of homozygous alleles.
Statistical analyses
LD analyses and pairwise LD plots of D0 were generated using the Haplo-
view 3.32 software (http://www.broad.mit.edu/haploview/haploview)
(Barrett et al., 2005). The statistical power to detect an association in
our case–control cohort was calculated by post-hoc tests implemented
in the G.Power software (Buchner et al., 1997) for an alpha (P-value) of
0.05 over effect sizes ranging from 0.1 (small) to 0.5 (medium). The
sample has 60% power to detect an effect size of 0.2 and greater than
88% power for effect sizes of 0.3 or more. Case–control association
tests for SNP markers were performed using unphased 3.0.10
(Dudbridge, 2008). Odds ratios (ORs) with corresponding 95% conﬁ-
dence intervals (95% CI) were calculated using Woolf’s formula with
Haldane’s correction. P-values were corrected for multiple comparisons
using Bonferroni’s correction. Case–control association tests for
the microsatellite marker D19S884 were performed using Clump 2.3
(www.mds.qmw.ac.uk/statgen/dcurtis/software.html) and Fisher’s exact
test. P-values for Fisher’s exact tests were calculated using GraphPad
Prism 5.00 for Windows (GraphPad Software, San Diego California USA,
.............................................................................................................................................................................................
Table I Primers used for qRT–PCR and microsatellite genotyping
Gene
or locus
Genebank
accession number
Location of amplicon Forward primer (50–30) Reverse primer (50–30)
18S AF176811 56–146 AGAAACGGCTACCACATCCAA CCTGTATTGTTATTTTTCGTCACTACC
FBN1 BC146854 1822-1882 AGCACACTCACGCGGACA AGATCCGGCCATTCTGTAAACA
FBN2 NM_001999 7545-7646 TCCAGTCAAGTTCTTCAGGCAC TGCGACTACTGGATGCCATTT
FBN3 NM_032447 1716-1787 TGGCGGCCACTACTGCAT TTGGTACAGTGGCCGTTCAC
LTBP-1 BC130289 3195-3322 CCCCAATGTCACGAAACAAGA AACCTTTCCCTTTGGGACACA
LTBP-2 NM_000428 3276-3382 CAGGAAAGGACACTGCCAAGA CCTCACAGGCCAGACAAGTGTA
D19S884 NC_000019 62 185–62 353 GGAGTTGCTCAGGGTC TCCCTCAACCCCCCGAGTTC
Fibrillin-3 and PCOS 831www.graphpad.com) and were Bonferroni corrected for multiple
comparisons.
Tissues for gene expression analyses
Collection of tissues for gene expression analyses was approved by the
Institution Review Boards of the University of Texas Southwestern
Medical Center, Dallas, USA, St Georges University of London, England
and The University of Adelaide, Australia. Informed written consent was
obtained prior to collection of tissues. Tissues were obtained from preme-
nopausal women undergoing procedures for benign gynaecologic con-
ditions. PCOS ovarian phenotype was diagnosed based on the presence
of three or more of the following criteria: enlarged ovarian volume
(.9 ml), 10 or more follicles of 2–8 mm in diameter, increased density
and volume of stroma or a thickened tunica (Mason et al., 1994). Speci-
mens were obtained from ovarian stroma/cortex (n ¼ 9 non-PCO and
4 PCO ovarian phenotype), ovarian follicles (n ¼ 3, .8 mm diameter)
and corpora lutea (n ¼ 3). The human ovarian cancer cell lines
OVCAR-3, OVCAR-5 and SKOV-3 (ascites derived) originating from
ovarian adenocarcinomas were obtained from the ATCC (Manassas,
VA, USA) and the granulosa tumour cell line KGN (Nishi et al., 2001)
was obtained with consent from its originators Professors Hajime
Nawata and Toshihiko Yanase of Kyushu University and Professor
Yoshihiro Nishi of Kurume University. Tissues and cells were either
stored in RNAlater (Ambion, Inc., Austin, TX) at 220
8C, or snap frozen
in liquid nitrogen and stored at 280
8C prior to RNA or protein isolation.
Gene expression analyses
Total RNA was isolated from 100 mg wet weight of stored stromal
tissue using 1 ml of Trizol (Invitrogen Australia Pty. Ltd., Mt Waverley,
VIC, Australia). Brieﬂy, tissue was homogenized for approximately 30 s
on ice using a polytron homogenizer before extraction was carried out
as per manufacturer’s instructions. Ten micrograms of total RNA was
treated with 2 U of DNase I (Ambion Inc, Austin, TX, USA) and ﬁrst-
strand complementary DNA (cDNA) was synthesized from the DNase-
treated RNA (2.5 mg) using 200 U Superscript III reverse transcriptase
(Invitrogen Australia Pty. Ltd.) and 500 ng random hexamers (Geneworks,
Thebarton, SA, Australia). Primers were designed against published
mRNA sequences using Primer Express software (Applied Biosystems).
Primer sequences for human FBN1, 2 and 3 and, LTBP-1 and -2 mRNA
are shown in Table I. Real-time PCR ampliﬁcation was performed using
an ABI PRISM 7000 sequence detection system (Applied Biosystems) by
adding 2.5 ml of appropriately diluted cDNA, 10 ml2   SYBR green
master mix (Applied Biosystems), 7.1 ml water and 0.2 ml of 12.5 mM
forward and reverse primers per well. Samples were ampliﬁed in duplicate
for one cycle at 508C for 2 min and 958C for 10 min, followed by 40 cycles
of 958C for 15 s and 608C for 1 min.
To generate a standard curve for each PCR assay, DNA standards for
each target sequence were prepared by sub-cloning the PCR products
of the corresponding target sequence into pCR2.1-TOPO vector (Invitro-
gen). The plasmid DNA was isolated and quantiﬁed using a Nanodrop
spectrophotometer (Nanodrop technologies, Wilmington, DE, USA).
DNA sequences were veriﬁed by automated sequencing (3730 DNA ana-
lyser, Applied Biosystems). Concentrations were calculated from absor-
bance at 260 nm. Plasmid DNA was serially diluted over three logs to
establish a standard curve in a range, determined for each sample,
which bounded the CT values obtained for samples (between 1 ng/ml
and 10 ag/ml). Concentration of each target was generated from the CT
and standard curve and was normalized to the concentration of 18S ribo-
somal RNA in each sample (calculated by the CT and standard curve for
18S). Gene expression of target sequences was subsequently expressed
as fmoles target sequence mRNA/nmole 18S ribosomal RNA. For each
gene the expression levels were normally distributed and comparisons
between each ovarian compartment and between PCO and non-PCO
tissues were compared by ANOVA, with no post hoc tests necessary as
no signiﬁcant differences were found.
Results
SNP and microsatellite analyses
Marker selection
We successfully genotyped 173 PCOS patients and 194 healthy
control subjects for 32 SNPs (Table II) within 82 kb of the FBN3
gene region (gene map in Fig. 1). We included SNPs (n ¼ 10) that
result in non-synonymous amino acid changes in the FBN3 protein
(Table II), with the intention of identifying PCOS-associated FBN3
mutations that might lead to defects in the functioning of the FBN3
protein either pre- or post-translationally. One SNP (rs17202741)
showed no heterogeneity in the population and another (rs12972954)
showedsigniﬁcantdeparturesfromHardy–Weinbergequilibrium(poss-
ibly indicating a problem with the primers used for genotyping). Both
were subsequently excluded from further analyses.
SNP association analyses
The results of the Sequenom genotyping analysis are displayed in
Table III. Relative frequencies for each allele of the 30 SNPs analysed
from PCOS and control subjects are summarized. Most alleles showed
almost identical population frequencies between PCOS and control
subjects. SNP association analyses performed with unphased software
(Dudbridge, 2008) found only one SNP (rs3813774) that achieved a
signiﬁcant (P ¼ 0.04 uncorrected) association with PCOS (Fig. 1). In
addition, case–control association analysis with Haploview software
(Barrett et al., 2005) found one SNP (rs3813774) that achieved a sig-
niﬁcant (P ¼ 0.04 uncorrected) association with PCOS (Table III).
Upon correction for multiple comparisons, however, the P-value for
this SNP no longer reached signiﬁcance.
Haplotype association and linkage analyses
In order to increase the potential to identify a PCOS-associated SNP
in the FBN3 genomic region we also performed LD haplotype associ-
ation analyses using Haploview software (Barrett et al., 2005). Haplo-
type association analysis can increase power to detect a signal from
other unknown SNPs (not in current databases) by performing the
association test on haplotype groups rather than individual SNPs.
Four haplotype blocks with 18 haplotypes were identiﬁed by Haplo-
view using the method described by Gabriel et al. (2002) (Fig. 2a).
Haplotype association frequencies, haplotype population frequencies
and D0 scores of these haplotype blocks are shown in Fig. 2. Haplotype
analysis failed to identify haplotypes that show signiﬁcant association
with PCOS. Given that the marker that led us to examine SNPs in
FBN3 (the microsatellite D19S884) is located in a region of low LD
(Fig. 2 and Urbanek et al., 2007), this result is perhaps not surprising
as haplotype blocks do not by deﬁnition exist in regions of low LD.
Microsatellite D19S884 association analysis
As we were unable to demonstrate association between the SNPs that
we typed in the FBN3 region and PCOS, we decided to genotype our
patient–control cohort for the previously associated microsatellite
832 Prodoehl et al................................
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Table II Information on the SNPs examined, including chromosomal and gene location, sequence variation and the
frequencies of their minor alleles for both control and PCOS patients, and the P-value for deviation of the genotype
frequencies from the Hardy–Weinberg equilibrium
Public id
a Chromsomal
location
b
Gene location Variation# Minor allele# Hardy–Weinberg
P-value
c
Allele frequency
d
Control Case
rs2287937 8036420 30 UTR G/C G 1.00 0.19 0.23
†rs12972954 8037849 Intronic C/T T – – –
rs10424096 8041170 Intronic A/G G 0.36 0.07 0.07
rs17261710 8042398 Intronic C/T C 0.67 0.17 0.18
rs2303169 8052114 Intronic G/A A 0.06 0.44 0.47
rs17160147 8054042 Intronic G/C C 0.17 0.70 0.71
††rs17202741 8062366 Coding A/C C – – –
AUG(M), CUG(L)
rs12151028 8064924 Intronic G/C C 0.06 0.86 0.88
rs7245429 8065362 Coding C/A A 0.57 0.40 0.42
CCT(P), CAT(H)
rs7245552 8065409 Silent C/A C 0.89 0.64 0.64
CCC(P), CCA(P)
rs12608849 8066334 Coding T/C T 0.76 0.25 0.28
TTC(F), ATC(I)
rs12150963 8066897 Coding G/C G 0.07 0.86 0.87
AAC(N), AAG(K)
rs3829817 8067450 Coding G/A A 0.71 0.75 0.77
CGG(R), CAG(Q)
rs3865464 8074340 Intronic C/T T 0.68 0.88 0.90
rs33967815 8074545 Coding G/A A 0.22 0.31 0.32
GGC(G), AGC(S)
rs10445638 8079428 Intronic G/A A 0.84 0.09 0.09
rs3813779 8080650 Intronic C/T T 0.23 0.53 0.56
rs8111335 8082361 Intronic T/C T 0.74 0.14 0.17
rs12975322 8082640 Coding G/A A 0.36 0.75 0.78
GTC(V), ATC(I)
rs4804063 8082945 Coding G/A G 0.41 0.81 0.83
AGT(S), GGT(G)
rs2086149 8083620 Intronic A/G A 0.27 0.30 0.30
rs35579498 8089871 Coding C/T T 0.86 0.04 0.04
CGG(R), TGG(W)
rs4527136 8092519 Intronic C/T T 1.00 0.44 0.47
rs35840170 8094812 Coding G/A A 1.00 0.97 0.97
GTC(V), ATC(I)
rs3813774 8102499 Silent C/T T 0.35 0.05 0.08
TGC(C), TGT(C)
rs12974280 8102508 Silent C/G G 0.57 0.62 0.64
TCC(S), TCG(S)
rs8112525 8107051 Intronic G/A A 0.04 0.09 0.10
rs2061776 8108373 Intronic A/G A 0.13 0.84 0.85
rs7246376 8109328 Coding C/T T 0.42 0.80 0.80
CCC(P), CTC(L)
rs12162237 8113070 Intronic T/C T 0.77 0.44 0.48
rs7252584 8113241 Intronic G/C C 0.64 0.15 0.20
rs7256533 8113721 Intronic T/C T 1.00 0.54 0.56
aReference SNP cluster identiﬁcation number.
bPosition of nucleotide on chromosome 19 in Build 35 of the human genome from UCSC (www.genome.ucsc.edu).
cP-value for deviation of genotype frequencies from Hardy–Weinberg equilibrium.
dMinor allelic frequency calculated using Haploview software.
†SNP displaying signiﬁcant departure from Hardy–Weinberg equilibrium.
††Potential SNP found not to be allelic. # The bases listed are those used in our design of primers and may represent the complimentary bases as listed in the Public Id.
Fibrillin-3 and PCOS 833marker D19S884. Microsatellite D19S884 allele frequencies for the
study group are shown in Table IV. The numbers of CA repeats
ranged from 14 to 24 in our cohort, and repeats of 22, 17, 18 and
20 were the most common at 26–27, 17, 12–13 and 11%, respect-
ively. The frequencies of each allele reported here are similar to
those published previously (Table IV).
Microsatellite allele association analyses were performed using
Fisher’s exact test and the Clump program. Fisher’s exact test did
not identify any alleles of D19S884 that were signiﬁcantly associated
with PCOS. Allele 10 (19 CA repeats) was the only allele that was sig-
niﬁcant (P ¼ 0.04 uncorrected), however, upon correction for mul-
tiple testing this P-value no longer approached signiﬁcance (P ¼
0.52) (Table IV). Clump analysis of D19S884 failed to identify associ-
ation between any of the 11 alleles detected and PCOS (data not
shown).
FBN and LTBP expression in human ovaries
We examined the expression of FBN1, 2 and 3 (Fig. 3), and LTBP-1 and
-2 mRNA (Fig. 4) in normal human ovarian tissues including stroma/
cortex (n ¼ 9 non-PCO and 4 PCO ovarian phenotype), follicles
(n ¼ 3) and corpora lutea (n ¼ 3) and ovarian cell lines. Expression
levels for each gene were not signiﬁcantly different between stroma,
follicles and corpora lutea. FBN1 mRNA levels were 50–100 times
greater than FBN2 and 200–1000-fold higher than FBN3 (Fig. 3).
The granulosa tumour cell line KGN displayed similar levels of FBN1
and 2 but lower levels of FBN3 expression when compared with
normal ovarian tissue samples (Fig. 3). OVCAR-3, OVCAR-5 and
SKOV-3 had lower levels of FBN1 than normal ovarian tissues and
KGN cells (Fig. 3). OVCAR-3 cells had very high levels of expression
of both FBN2 and 3 expression compared with the other cell lines and
the ovarian tissues (Fig. 3).
LTBP-1 expression levels were .3-fold greater than LTBP-2 in
normal ovarian tissues (Fig. 4). OVCAR-3, OVCAR-5 and SKOV-3
had lower levels of LTBP-2 than normal ovarian tissues, but LTBP-1
expression was variable across the cell lines; with OVCAR-3 having
the highest levels of expression (Fig. 4). Correlation analyses were
conducted and FBN1 expression signiﬁcantly correlated with FBN2
(P , 0.001) and LTBP-1 (P , 0.01) and FBN2 with LTBP-1 (P ,
0.001) across all tissues (Fig. 5).
Discussion
We have conducted a case–control study of PCOS examining the
genotypes of 30 SNPs, including 10 functional SNPs, in an 82 kb
region of chromosome 19 ﬂanking FBN3. In our cohort, we also gen-
otyped the microsatellite marker D19S884, previously reported to be
associated with PCOS by familial linkage analyses and located within
intron 55 of FBN3. In addition, we examined the expression of the
three FBNs and two of the LTBPs( LTBP-1 and -2) in ovarian tissues.
We conclude that if FBN3 is involved in the aetiology of PCOS then
its role is not readily apparent from these studies.
Tagging SNPs were chosen to span an 82 kb region of the FBN3
gene, which ﬂanks the previously associated microsatellite marker
D19S884, such that 100% of SNP alleles with minor allele frequen-
cies .5% in this region were captured with an r
2 value of .0.8. Thus,
we would have expected to have been able to identify any common
SNP within this region of 19p13.2 that showed signiﬁcant association
Figure 1 Unphased association analysis for 30 SNPs all of which can be mapped within an 82 kb region spanning FBN3. Chromosomal position is
plottedversus –logP-valueforchi-squaretestsofassociationofeachmarkerwithPCOS.Thedottedlinesrepresentthecut-offmarkforP-valuesreaching
signiﬁcance before Bonferroni’s correction for multiple testing (P   0.05 and P   0.01). The position of introns and exons of the two genes (CCL25 and
FBN3)relativeto the SNPs analysedaredisplayedbelowthe graph. Markersare1 rs2287936, 2 rs10424096,3 rs17261710, 4 rs2303169,5 rs17160147,
6 rs12151028, 7 rs7245429, 8 rs7245552, 9 rs12608849, 10 rs12150963, 11 rs3829817, 12 rs3865464, 13 rs33967815, 14 rs10445638, 15 rs3813779,
16 rs8111335, 17 rs12975322, 18 rs4804063, 19 rs2086149, 20 rs35579498, 21 rs4527136, 22 rs35840170, 23 rs3813774, 24 rs12974280, 25
rs8112525, 26 rs2061776, 27 rs7246376, 28 rs12162237, 29 rs7252584 and 30 rs7256533.
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Table III Association analysis of SNPs within the FBN3 genewith PCOS showing chromosomal position, chi-square values, P-values, odds ratios, conﬁdence limits
and allelic frequencies for each SNP
Marker id
a Chromosomal
postion
b
x
2
(Haploview)
c
P-value
(Haploview)
d
2log
P-value
Odds
ratio
e
95%
low
f
95%
high
g
P-value
corrected
(Haploview)
h
Minor allele Major allele
Case
frequency
Control
frequency
Case
number
i
Control
number
j
Case
frequency
Control
frequency
Case
number
i
Control
number
j
rs2297936 8036420 1.81 (1.92) 0.18 (0.17) 0.74 1.28 0.89 1.83 1 (1) 0.23 0.19 80 74 0.77 0.81 266 314
rs10424096 8041170 0.21 (0.11) 0.64 (0.74) 0.19 1.15 0.64 2.04 1 (1) 0.07 0.07 25 24 0.93 0.93 311 342
rs17261710 8042398 0.17 (0.20) 0.68 (0.66) 0.17 0.92 0.63 1.35 1 (1) 0.18 0.16 61 64 0.82 0.84 285 324
rs2303169 8052114 1.08 (1.08) 0.30 (0.30) 0.52 0.86 0.63 1.17 1 (1) 0.47 0.44 163 169 0.53 0.56 181 219
rs17160147 8054042 0.03 (0.03) 0.85 (0.85) 0.07 1.03 0.74 1.43 1 (1) 0.30 0.30 101 117 0.70 0.70 241 271
rs12151028 8064924 0.32 (0.32) 0.57 (0.57) 0.24 1.13 0.72 1.77 1 (1) 0.13 0.14 43 54 0.88 0.86 301 334
rs7245429 8065362 0.41 (0.41) 0.52 (0.52) 0.28 0.91 0.67 1.22 1 (1) 0.42 0.39 142 153 0.58 0.61 198 235
rs7245552 8065409 0.002 (0.002) 0.96 (0.96) 0.02 0.99 0.73 1.35 1 (1) 0.36 0.36 121 138 0.64 0.64 219 248
rs12608849 8066334 1.05 (1.05) 0.31 (0.31) 0.51 1.19 0.86 1.64 1 (1) 0.28 0.25 97 96 0.72 0.75 245 288
rs12150963 8066897 0.21 (0.21) 0.65 (0.65) 0.19 0.90 0.58 1.42 1 (1) 0.13 0.14 43 53 0.87 0.86 299 333
rs3829817 8067450 0.26 (0.22) 0.61 (0.64) 0.21 1.09 0.78 1.54 1 (1) 0.23 0.25 80 96 0.77 0.75 266 292
rs3865464 8074340 1.08 (1.08) 0.30 (0.30) 0.52 0.78 0.50 1.23 1 (1) 0.10 0.12 34 48 0.90 0.88 308 340
rs33967815 8074545 0.03 (0.06) 0.85 (0.81) 0.07 1.03 0.76 1.40 1 (1) 0.32 0.31 111 122 0.68 0.69 235 266
rs10445638 8079428 0.07 (0.07) 0.79 (0.79) 0.10 0.93 0.55 1.57 1 (1) 0.09 0.09 31 33 0.91 0.91 309 353
rs3813779 8080650 0.68 (0.57) 0.41 (45) 0.39 0.88 0.67 1.18 1 (1) 0.44 0.47 150 181 0.56 0.53 194 207
rs8111335 8082361 1.80 (1.81) 0.18 (0.18) 0.74 1.32 0.86 2.02 1 (1) 0.17 0.14 59 53 0.83 0.86 283 335
rs12975322 8082640 0.88 (0.88) 0.35 (0.35) 0.46 1.18 0.83 1.67 1 (1) 0.22 0.25 75 96 0.78 0.75 269 292
rs4804063 8082945 0.38 (0.38) 0.54 (0.54) 0.27 0.89 0.62 1.28 1 (1) 0.17 0.19 59 73 0.83 0.81 285 313
rs2086149 8083620 0.03 (0.05) 0.87 (0.83) 0.06 0.97 0.71 1.33 1 (1) 0.30 0.30 104 114 0.70 0.70 240 270
rs35579498 8089871 0.02 (0.02) 0.89 (0.89) 0.05 1.06 0.49 2.26 1 (1) 0.04 0.04 14 15 0.96 0.96 328 371
rs4527136 8092519 0.54 (0.54) 0.46 (0.46) 0.34 1.12 0.83 1.50 1 (1) 0.46 0.44 159 169 0.54 0.56 183 217
rs35840170 8094812 0.35 (0.35) 0.55 (0.55) 0.26 1.30 0.54 3.11 1 (1) 0.03 0.03 9 13 0.97 0.97 333 371
rs3813774 8102499 4.29 (4.36) 0.04 (0.04) 1.46 1.88 1.00 3.52 1 (1) 0.08 0.05 29 18 0.92 0.95 317 370
rs12974280 8102508 0.09 (0.09) 0.76 (0.76) 0.12 0.95 0.70 1.30 1 (1) 0.37 0.38 125 146 0.63 0.62 217 242
rs8112525 8107051 0.27 (0.29) 0.61 (0.59) 0.21 0.88 0.54 1.42 1 (1) 0.10 0.09 33 33 0.90 0.91 309 353
rs2061776 8108373 0.17 (0.17) 0.68 (0.68) 0.17 1.09 0.71 1.67 1 (1) 0.15 0.16 50 61 0.85 0.84 290 325
rs7246376 8109328 0.12 (0.12) 0.73 (0.73) 0.14 0.94 0.66 1.34 1 (1) 0.20 0.21 67 80 0.80 0.79 275 308
rs12162237 8113070 1.64 (1.64) 0.20 (0.20) 0.70 1.21 0.90 1.62 1 (1) 0.48 0.44 166 168 0.52 0.56 178 218
rs7252584 8113241 2.36 (2.36) 0.12 (0.12) 0.92 0.74 0.50 1.08 1 (1) 0.20 0.15 67 59 0.80 0.85 273 325
rs7256533 8113721 0.29 (0.29) 0.59 (0.59) 0.23 0.92 0.69 1.23 1 (1) 0.44 0.46 150 178 0.56 0.54 190 208
aReference SNP cluster ID.
bPosition of nucleotide on chromosome 19 in Build 35 of the human genome from UCSC (www.genome.ucsc.edu).
cChi-squared values calculated using unphased 3.0.10 software.
dP-value of odds ratio.
eOdds ratios were calculated using unphased 3.0.10 software.
fLower bound on the 95% conﬁdence interval for the odds ratio.
gUpper bound on the 95% conﬁdence interval for the odds ratio.
hP-value corrected for multiple testing (Bonferroni correction).
iNumber of alleles in control subjects.
jNumber of alleles in case subjects.
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5with PCOS. None of the 30 SNPs we tested had allele frequencies
that were signiﬁcantly different between controls and PCOS patients
once corrected for multiple testing.
Microsatellite D19S884 is located in a non-conserved intronic
region that displays low levels of LD, thus it remains possible that a
causal SNP is located within this region. The closest SNP markers
to D19S884 (chromosomal position 8056140) that were analysed
here were rs17160147 and rs1251028, which are located at
2098 bp 30 and 8784 bp 50 of D19S884, respectively. There is at
least one other SNP (rs1246064) in this region that was not analysed,
nor captured by our tagging SNPs, and is heterogeneous in the CEU
population. It is, however, unlikely that this SNP is causal for PCOS
as it does not result in changes to protein sequence and was not
found to be associated with PCOS in another study (Urbanek et al.,
2007). There are other SNPs in this region that are heterogeneous
in either African (rs8102892, rs8112982), Asian (rs8105886,
rs17160153) or both populations (rs17160151, rs12984611) but
these are not heterogeneous in a European population and hence unli-
kely to be causal in an Australian population. As we did not ﬁnd any
SNP in the FBN3 gene region that showed any signiﬁcant association
with PCOS, we examined the association of the microsatellite
marker D19S884 in our cohort. Previous studies identiﬁed allele 8
(17 CA di-nucleotide repeats) as segregating with PCOS (Tucci
et al., 2001; Urbanek et al., 2007). However, we were unable to ident-
ify any allele of the microsatellite that showed any signiﬁcant associ-
ation with PCOS in our cohort, after correcting for multiple testing.
The results presented here would appear to be in disagreement
with other studies that found strong association between D19S884
Figure 2 (A) Haplotypes predicted by Haploview. Four blocks were observed with the haplotpes of each block shown. Darker lines between hap-
lotypes indicate a higher percentage of association with the linked haplotypes. Haplotype frequencies are indicated in red. D0 values for LD are indi-
cated below each haplotype block. Chromosomal positions were taken from those reported for build 35 of the UCSC genome website (http://www.
genome.ucsc.edu/). (B) Haploview generated graphic analysis of LD in an 82 kb region of chromosome 19 spanning FBN3. The relative position of
each of the 31 markers (30 SNPs and D19S884, which is indicated with an arrow) on chromosome 19p13.2 is indicated by the vertical lines on the
chromosomal map (top) and the proportion of LD (displayed as D0/LOD) is displayed below each marker. Haplotype blocks are indicated by dark
lines. Strong LD (D0 ¼ 1, LOD   2) is indicated by red, lighter shades pink indicate varying degrees of LD with lighter shades displaying less than darker
(D0 , 1, LOD   2) and white indicates low LD (D0 , 1, LOD , 2).
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Table IV For each allele in microsatellite D19S884 this table lists information on the sizes of the amplicons using either the current primers or those for
amplimer AFMa299zc5, the numbers of CA repeats, the identiﬁcation numbers ascribed to alleles by a previous study (Urbanek et al., 2005), the frequencies of
each allele listed in Genbank and in a previous study (Villuendas et al., 2003) and that obtained in the current experiment, and the P-value for association of an
allele with PCOS calculated using Fisher’s exact test
Amplicon sizes* Number
of CA
repeats
Allele identiﬁcation
number
Allele frequency
Current
data
Amplimer
AFMa299zc5
Urbanek
et al.
Genbank Genbank† Data of Villuendas
et al.
Current data
Controls PCOS Controls
(number
of alleles)
PCOS
(number
of alleles)
P-value
a Odds
ratio
95%
low
b
95%
high
c
Corrected
P-value
d
214 12 – 0.01
216 13 0.01 –
160 218 14 A5 10 0.12 0.07 0.01 0.09 (33) 0.06 (21) 0.26 1.44 1.22 1.69 1.00
162 220 15 A6 7 0.02 – 0.01 0.02 (6) 0.01 (5) 1.00 1.07 0.52 2.22 1.00
164 222 16 A7 2 0.11 0.12 0.07 0.10 (38) 0.12 (40) 0.47 0.83 0.74 0.93 1.00
166 224 17 A8 4 0.12 0.11 0.12 0.17 (64) 0.17 (60) 0.77 0.94 0.87 1.02 1.00
168 226 18 A9 1 0.12 0.17 0.13 0.12 (46) 0.13 (44) 0.74 0.92 0.84 1.02 1.00
170 228 19 A10 9 0.05 0.08 0.03 0.06 (22) 0.03 (9) 0.04 2.25 1.64 3.09 0.52
172 230 20 A11 3 0.11 0.09 0.11 0.11 (42) 0.11 (42) 1.00 0.98 0.88 1.10 1.00
174 232 21 A12 6 0.04 0.04 0.07 0.05 (18) 0.06 (20) 0.51 0.79 0.64 0.99 1.00
176 234 22 A13 5 0.25 0.27 0.28 0.26 (99) 0.27 (94) 0.62 0.92 0.87 0.97 1.00
178 236 23 A14 8 0.05 0.03 0.05 0.03 (13) 0.01 (4) 0.05 2.96 1.54 5.68 0.63
180 238 24 0.02 0.03 0.01 (4) 0.03 (9) 0.16 0.39 0.19 0.80 1.00
182 240 25 ,0.00 (1) 0.00 (0) 1.00 – – – 1.00
*To detect microsatellite D19S884 we designed different primers (Table I) to that of amplimer AFMa299zc5 listed in Genbank, hence the current amplicons differ in size.
†Frequencies of alleles listed in Genbank are from 8 CEPH families composed of 56 individuals as described for the microsatellite polymorphism rs3222751 under reference submission ss4914553.
aP-value for association of a microsatellite allele with PCOS calculated by Fisher’s exact test.
bLower bound on the 95% conﬁdence interval for the odds ratio.
cUpper bound on the 95% conﬁdence interval for the odds ratio.
dP-value corrected for multiple testing (Bonferroni correction).
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7and PCOS (Tucci et al., 2001; Urbanek et al., 2007). Both studies were
conducted on subjects recruited solely from the USA and who fulﬁlled
the 1990 NIH criteria. One study (Tucci et al., 2001) was a case–
control study whereas the other (Urbanek et al., 2007) was a family-
based study. We also recruited subjects of Caucasian background
from the Australian population who fulﬁlled the 1990 NIH criteria
for a case–control study. It is possible but unlikely that there are
differences in genetic background with regard to PCOS between the
Australian population and that of the USA. While the number of sub-
jects in our study is low, our power calculations suggest that we had
enough power to detect mutations that have a moderate (0.3)
effect size and our numbers are much higher (173/194 PCOS/
control subjects) than two previous case–control studies (Tucci
et al., 2001; Villuendas et al., 2003) having 85/87 and 108/66
PCOS/control subjects, respectively. Our study is therefore more
likely to be reﬂective of population allele frequencies and less prone
to sampling bias. Despite this, it is possible that our numbers were
too low to detect association of D19S884 with PCOS in the Australian
population.
The expression of FBN1, 2 and 3 and LTBP-1 and -2 were examined
in PCO ovarian stroma/cortex and non-PCO stroma/cortex, follicles
and corpora lutea and clear patterns emerged. Firstly, there were no
differences between stroma from ovaries with a PCO phenotype and
those from non-PCO ovaries in any of the genes examined. In all the
tissues examined, the expression of FBN1 was far greater than FBN2,
which was far greater than FBN3, which was barely detectible. A
similar pattern of expression was previously observed in bovine
tunica and stroma of the cortex (Prodoehl et al., 2009). In our pre-
vious study, we found that in the bovine ovary, the expression of
FBN1 within follicles was conﬁned to the theca interna and in the
tunica and stroma (corpora lutea were not examined) (Prodoehl
et al., 2009). In the current study we found that the expression of
LTBP-1 was greater than that of LTBP-2, which was also observed in
the bovine tunica and stroma of the cortex (Prodoehl et al., 2009).
In bovine ovaries, the expression of LTBP-1 was localized to the
tunica and stroma of the cortex and in follicles in the inner area of
the theca externa (Prodoehl et al., 2009). Additionally, the immunolo-
calization pattern of FBN1 and LTBP-1 were ﬁbrillar in the tunica and
stroma of the cortex and in the thecal layers, suggesting that they
are both associated with microﬁbrils as has been observed previously
(Isogai et al., 2003). Expression of FBN1 and 2 and LTBP-1 in the
ovarian tissues examined here were correlated with each other. In
bovine tunica and cortical stromal samples all three FBNs were corre-
lated with LTBP-2 and not LTBP-1 (Prodoehl et al., 2009). This suggests
that there is some degree of coordinate regulation amongst these
genes in both humans and in the bovine.
Figure 3 Expression of FBN1 (A), FBN2 (B) and FBN3 (C) mRNA
in human ovarian tissues and from the human ovarian tumour cell
lines KGN, OVCAR-3, OVCAR-5 and SKOV-3. Data are presented
as the mean values+SEM expressed as fmoles RNA/nmole 18S
ribosomal RNA, n ¼ 4, 9, 3 and 3 for the PCO stroma/cortex and
non-PCO stroma/cortex, follicles and corpora lutea (CL),
respectively.
Figure 4 Expression of LTBP-1 (A) and LTBP-2 (B) mRNA in
human ovarian tissues and from the human ovarian tumour cell
lines KGN, OVCAR-3, OVCAR-5 and SKOV-3. Data are presented
as the mean values+SEM expressed as fmoles RNA/nmole 18S
ribosomal RNA, n ¼ 4, 9, 3 and 3 for the PCO stroma/cortex and
non-PCO stroma/cortex, follicles and corpora lutea (CL), respectively.
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expression was also examined in human ovarian cancer cell lines
OVCAR-3, OVCAR-5 and SKOV-3 (ascites derived) derived from
ovarian adenocarcinoma, and in KGN cells which have a granulosa
cell phenotype (Nishi et al., 2001). The expression levels of FBN1, 2
and 3 and LTBP-1 in the KGN cells was generally similar to that of
the other ovarian tissues examined. The expression of these genes
was much lower in the OVCAR-5 and SKOV-3 cells, in agreement
with the localization of FBN1 and LTBP-1 and -2 in the bovine where
no localization to the ovarian surface epithelium was observed
(Prodoehl et al., 2009). However, OVCAR-3 had elevated levels of
FBN2, 3, and LTBP-1 relative to normal ovarian tissues and other
ovarian cancer cell lines.
It appears, from our genetic analysis, that the marker D19S884 and
its associated gene, FBN3, have little or no impact on PCOS pathology
in the Australian population. We cannot, however, rule out the possi-
bility that other markers in the region of chromosome 19p13.2 are
associated. Additionally our study of expression of ﬁve members of
the ﬁbrillin family in human ovaries found very low levels of FBN3,
but our study also cannot rule out that alterations in FBN3 expression
occur in other organs or tissues such as the anterior pituitary,
inﬂuencing hormonal regulation of the ovary or adipose tissue. It is
also possible that a genetic lesion in the FBN3 gene associated with
PCOS pathology may cause functional changes in the protein’s struc-
ture without affecting its expression levels. We conclude that if FBN3 is
involved in the aetiology of PCOS then its role is not readily apparent
from these studies.
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